Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005145 · ClinicalTrials.gov registry record · NA
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
A NA study of Sepsis and Bacteremia, sponsored by Sunnybrook Health Sciences Centre.
- Completed
- Registry status
- NA
- Development phase
- 3,622
- Enrollment target
- 20
- Study locations
NCT03005145: Completed NA study of Sepsis and Bacteremia, sponsored by Sunnybrook Health Sciences Centre.
NCT03005145 is a NA study of Sepsis and Bacteremia that has completed, run by Sunnybrook Health Sciences Centre. The registered enrollment target is 3,622 participants, below the 6,524-participant average among 90 other Sepsis trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03005145, a NA study of Sepsis and Bacteremia, has completed, sponsored by Sunnybrook Health Sciences Centre.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,622 participants
- Enrollment target
- 20
- Study locations
Study Summary
The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declining new drug development. Up to 30-50% of antibiotic use is inappropriate, and excessive durations of treatment are the greatest contributor to inappropriate use. Shorter duration treatment (≤7 days) has been shown in meta-analyses to be as effective as longer antibiotic treatment for a range of mild to moderate infections. A landmark trial in critically ill patients with ventilator-associated pneumonia showed that mortality and relapse rates were non-inferior in patients who received 8 vs 15 days of treatment. Similar adequately powered randomized trial evidence is lacking for the treatment of patients with bloodstream infections caused by a wide spectrum of organisms.
Primary Outcome
Survival at 90-days recorded as alive or dead at day 90 following index positive blood culture
Conditions Studied
Interventions
- OTHER 7 days of adequate antibiotic treatment
- OTHER 14 days of adequate antibiotic treatment.
Study Locations (20)
Victoria
- Ballarat Hospital - Ballarat
- Bendigo Hospital - Bendigo
- Casey Hospital - Berwick
- Monash Medical Centre - Clayton
- Dandenong Hospital- Monash Health - Dandenong
- Frankston Hospital - Frankston
- Peninsula Private Hospital - Langwarrin
- Cabrini Health - Malvern
New South Wales
- Bankstown Hospital - Bankstown
- St Vincent's Hospital - Darlinghurst
- St. George Hospital - Kogarah
- John Hunter Hospital - New Lambton Heights
- Westmead Hospital - Westmead
- Wollongong Hospital ICU - Wollongong
Western Australia
- Fiona Stanley Hospital - Murdoch
- St John of God Hospital - Subiaco
New York
- NYU School of Medicine - New York
Ohio
- Cleveland Clinic - Cleveland
Queensland
- Sunshine Coast University Hospital - Birtinya
Alberta
- Foothills Hospital - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,622 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2023-08-03 |
| Phase | NA |
What the finished NCT03005145 record still lists
NCT03005145 is an interventional study that assigns participants to a tested intervention. Its 3,622 participants enrollment target places it among the larger protocols in the corpus, below the 6,524-participant average among 90 other Sepsis trials with a reported enrollment target (44% lower).
The record links to 6 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which 7 days of adequate antibiotic treatment is the first listed.
NCT03005145 names 20 study sites across 7 states, led by Victoria, New South Wales, Western Australia.
Frequently Asked Questions
What is clinical trial NCT03005145 about?
NCT03005145 is a clinical study titled "Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness". The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declinin...
What is the current status of trial NCT03005145?
This trial is currently completed. It is a NA study. The enrollment target is 3,622 participants. The study started on 2017-02-24. Estimated completion is 2023-08-03.
What conditions does trial NCT03005145 study?
This clinical trial studies the following conditions: Sepsis, Bacteremia, Critically Ill, Mortality, Intensive Care.
What interventions are being tested in trial NCT03005145?
The interventions under investigation include: 7 days of adequate antibiotic treatment (OTHER), 14 days of adequate antibiotic treatment. (OTHER).
Who is sponsoring clinical trial NCT03005145?
This trial is sponsored by Sunnybrook Health Sciences Centre, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03005145 being conducted?
This trial has 20 study locations across New York, Ohio, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03005145's enrollment target sits among peer trials
3,622 12th of 90 higher than 79 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
BLOOM: Pragmatic Feasibility Trial
RECRUITING · NA
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06354920 · 3,624 participants · NA
M-Well Bonding Bundle to Improve Patient-Physician Relationships
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
- NCT06501118 · 3,600 participants · NA
Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients
- NCT06919419 · 3,600 participants · NA
HOTSPOT Study: Implement and Evaluate the PrEP (Pre-exposure Prophylaxis) Implementation Strategy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI